• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

ELEMENTARY, MY DEAR WATSON

Mad Hedge AI

(NVDA), (MSFT), (JNJ), (SSMNY), (ICAD), (GEHC)

Today, let’s spotlight the inner workings of our bodies. And let me tell you, it's not always a pretty picture.

Think about it: you're going about your day, feeling like a million bucks, thinking everything is hunky-dory. 

But little do you know, there could be a ticking time bomb inside you, just waiting to go off. It could be a sneaky cancer, a bulging aneurysm, or a heart attack waiting to happen.

In fact, 70% of all heart attacks come out of nowhere, like a sucker punch to the gut. No warning signs, no red flags, just bam! You're down for the count.

It's the same story with cancer. The ones that end up being a death sentence are usually the ones that we don't routinely test for. Pancreatic cancer, and brain cancer - they're like silent assassins, lurking in the shadows until it's too late.

Don't even get me started on Parkinson's. By the time you start shaking like a leaf, 50% of your brain cells have already kicked the bucket.

It's enough to make you want to stick your head in the sand and pretend everything is fine. But trust me, that's not the way to go. You're going to find out eventually, and it's better to know sooner rather than later.

The good news is, thanks to some seriously cool AI tech, we might finally have a way to catch these sneaky diseases before they can do too much damage.

First up, we've got NVIDIA (NVDA). These guys are the kings of AI, and they're not messing around when it comes to healthcare. 

They've got a platform called Clara that's all about using AI to detect cancer and heart disease early. And with a market cap of over a trillion bucks, you know they mean business.

Next in line is Microsoft (MSFT). They may be known for Windows and Office, but they're also making big moves in healthcare AI. Their Azure platform is like a Swiss army knife for doctors, helping them analyze medical images, crunch data, and even predict who's at risk for certain diseases.

But it's not just the tech giants getting in on the action. Healthcare heavyweights like Johnson & Johnson (JNJ) and Siemens Healthineers (SMMNY) are also betting big on AI. They're leveraging it to develop new cancer therapies, improve surgical outcomes, and even personalize treatment plans.

The global AI in healthcare market is set to explode like a supernova, shooting up to a jaw-dropping $187.95 billion by 2030. And guess what's leading the charge? You got it - cancer diagnostics. 

You know how cancer screenings can sometimes be like the boy who cried wolf, with false alarms left and right? 

Well, AI algorithms are here to save the day. They're like the superhero that swoops in and reduces those pesky false positives, which means fewer unnecessary biopsies and procedures. It's a win-win for everyone.

Aside from the heavyweights in AI and healthcare, there are also some lesser-known names working in this field.

There’s iCAD (ICAD), who’s like the king of the castle when it comes to AI-powered cancer detection, especially in the breast health arena. 

Their ProFound AI software is like a trusty sidekick for radiologists, helping them interpret mammograms like a pro. It's like having a cheat code for earlier and more accurate cancer diagnoses.

Another name working on this is Zebra Medical Vision. They're like the pioneers of the Wild West, blazing trails in AI-based medical imaging analysis. Their AI algorithms are like a bunch of little detectives, scouring medical scans for any signs of trouble - breast cancer, heart disease, fatty liver, you name it. 

And while Zebra Medical isn’t traded publicly (yet), they're rubbing elbows with the bigwigs in healthcare. Keep an eye out for these guys - they might just pull off an IPO or get scooped up by one of the big players.

Then, there’s GE Healthcare (GEHC). They're like the 800-pound gorilla in the room when it comes to medical tech. 

But don't let their size fool you - they're all about the AI game these days. Their Edison platform? It's like a magic wand that integrates AI into all sorts of medical imaging and diagnostic tools, with a special knack for sniffing out cancer and keeping hearts ticking.

So how does all this AI magic work? Well, it's all about teaching computers to think like humans. Researchers at the Beckman Institute in Illinois have developed an AI model that can spot tumors and diseases in medical images like a pro. 

But here's the really cool part: it can also explain its thought process, like a medical Sherlock Holmes.

The model creates a visual map that highlights the areas it thinks are most suspicious. It's like a treasure map for doctors, leading them straight to the problem spots. 

And if a patient asks how the AI made its diagnosis, the doc can just point to the map and say, "Here's your answer, plain as day."

The researchers tested their model on a bunch of different medical images, from mammograms to retina scans to chest X-rays. And you know what? It held its own against the existing AI systems out there. 

We're talking accuracy rates of up to 99% in some cases.

And here's the real game-changer: this model isn't just a one-trick pony. The researchers think it could be used to detect all kinds of abnormalities all over the body, from head to toe.

Now, I know you're all wondering: when is this AI revolution going to take over cancer and heart disease detection? 

Well, there's no crystal ball, but it's safe to say it's already happening. In the short term - I'm talking the next 1-3 years - expect to see AI-powered tools for image analysis and risk assessment really take off, especially in areas like breast cancer and heart disease. 

We're also going to see more of these AI solutions getting the green light from the powers that be, and a whole lot of brainpower and cash flowing into early detection and personalized medicine.

But in the medium to long haul - I'm talking 5-10+ years down the line - that's when things are really going to get interesting. 

We're going to see AI really start to shake things up in clinical workflows across the board. It's going to be like having a super-smart robot assistant in every specialty. 

So here's my take: if you're not using AI to keep tabs on your health, you're missing out. It's like having a team of super-smart doctors working around the clock, just for you.

And if you're looking to get in on the action, keep your eyes on the companies I mentioned. They're the ones leading the charge in healthcare AI, and I have a feeling they're just getting started.

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://www.madhedgefundtrader.com/wp-content/uploads/2024/06/Screenshot-2024-06-14-171646.jpg 528 930 Douglas Davenport https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Douglas Davenport2024-06-14 17:22:442024-06-14 17:22:44ELEMENTARY, MY DEAR WATSON

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Link to: June 14, 2024 Link to: June 14, 2024 June 14, 2024 Link to: The Market Outlook for the Week Ahead, or The Three-Horse Race Link to: The Market Outlook for the Week Ahead, or The Three-Horse Race The Market Outlook for the Week Ahead, or The Three-Horse Race
Scroll to top